In early March, the first patient was enrolled and treated in Cynata’s Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease (aGvHD).
Learn more here: https://bit.ly/4b0nkG7
Cynata has updated the market on the positive progress of its diabetic foot ulcers clinical trial.
Read Stockhead’s coverage here https://bit.ly/3P0mb8N
Cynata is analysing wound surface areas in the first 16 patients of its Phase 1 trial for CYP-006TK, its off-the-shelf iPSC-derived MSC topical dressing for diabetic foot ulcers, with results expected by Q1 2024.
Following regulatory and ethics clearance to initiate a Phase 2 clinical trial for CYP-001 in patients with High-Risk acute Graft versus Host Disease at clinical sites in Turkey, Cynata plans to establish multiple clinical centers, commencing site initiation visits in the next 1-2 months.
Following the completion of the site initiation visit at Weill Cornell Medical Center in New York for the Phase 2 clinical trial of CYP-001 in High-Risk acute Graft versus Host Disease (HR-aGvHD), Dr Kilian Kelly spoke with Proactive Investors about this important milestone.